ReviewCytokine & growth factor reviews
Directing systemic oncolytic viral delivery to tumors via carrier cells.
Review in Cytokine & growth factor reviews. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma.Journal of neurosurgery · 2022Trial
- Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Mesenchymal Stem Cells in Cancer Therapy.Advances in experimental medicine and biology · 2025Review
- Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis.Journal of translational medicine · 2024Review
- Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy.Cancer immunology, immunotherapy : CII · 2024Article
- Review
- Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner.Biomarker research · 2024Review
- Enhancement of Therapeutic Potential of Oncolytic Virus with Homologous Tumor Cell Membranes for Pancreatic Cancer.IET nanobiotechnology · 2024Article
- Nanocarriers for cancer nano-immunotherapy.Drug delivery and translational research · 2023Review
- Enhanced tumor targeting and timely viral release of mesenchymal stem cells/oncolytic virus complex due to GRP78 and inducible E1B55K expressions greatly increase the antitumor effect of systemic treatment.Molecular therapy oncolytics · 2022Article
- Mesenchymal stem/stromal cells in cancer therapy.Journal of hematology & oncology · 2021Review
- Mesenchymal stem cells and oncolytic viruses: joining forces against cancer.Journal for immunotherapy of cancer · 2021Review
- Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment.Molecular therapy oncolytics · 2020Article
- Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma.Molecular therapy oncolytics · 2020Article
- Engineered stem cells targeting multiple cell surface receptors in tumors.Stem cells (Dayton, Ohio) · 2020Review
- Arming Mesenchymal Stromal/Stem Cells Against Cancer: Has the Time Come?Frontiers in pharmacology · 2020Review
- p19Arf sensitizes B16 melanoma cells to interferon-β delivered via mesenchymal stem cells in vitro.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020Article
- Oncolytic viruses: overcoming translational challenges.The Journal of clinical investigation · 2019Review
- Matrix metalloproteinase-1 facilitates MSC migration via cleavage of IGF-2/IGFBP2 complex.FEBS open bio · 2018Article
- Gene Delivery in Neuro-Oncology.Current oncology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The systemic administration of oncolytic virus (OV) is often inefficient due to clearance of the virus by host defense mechanism and spurious targeting of non-cancer tissues through the bloodstream. Cell mediated OV delivery could hide the virus from host defenses and direct them toward tumors: Mesenchymal and neural stem cells have been described to possess tumor-homing ability as well as the capacity to deliver OVs. In this review, we will focus on approaches where OV and carrier cells are utilized for cancer therapy. Effective cellular internalization and replication of OVs need to occur both in cancer and carrier cells. We thus will discuss the current challenges faced by the use of OV delivery via carrier cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.